Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

5alpha-reductase type 1 inhibitors from Merck & Co.

June 21, 1996

Botulinum toxin type A as dermatology remedy

June 14, 1996

Positive phase III results for Phytopharm's Zemaphyte

June 14, 1996

Amgen reveals polypeptide KGF analogues

June 14, 1996

Excellent preclinical results of Repel announced

June 14, 1996

New topical corticosteroids from Hoechst

June 14, 1996

Favorable trial results with interferon gamma-1b for atopic dermatitis and keloids

June 7, 1996

Collagen Corp. acquires distribution rights to Tissue Technologies' ePTFE implant

June 7, 1996

Synthetic retinoid analogue cleared for U.S. market

June 7, 1996

Oclassen obtains rights to 5-MOP

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...